← Back to Clinical Trials
Recruiting NCT06723522

NCT06723522 High Definition Transcranial Direct Current Stimulation of Right Inferior Frontal Gyrus to Improve Social Impairments in Children with Autism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06723522
Status Recruiting
Phase
Sponsor Central South University
Condition Autism Spectrum Disorder (ASD)
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-08-30
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
HD-tDCSSham (No Treatment)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-08-30 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn if high definition transcranial direct current stimulation (HD-tDCS) of right inferior frontal gyrus works to improve social impairments in children with autism spectrum disorder (ASD). It will also learn about the underlying brain mechanism. The main questions it aims to answer are: * Does HD-tDCS of right inferior frontal gyrus improve social impairments in children with ASD? * What are the underlying brain mechanisms by which the HD-tDCS of right inferior frontal gyrus improves social impairments in children with ASD? Researchers will compare participants received active HD-tDCS to controls received sham HD-tDCS (performed to mimic the sensation induced by real HD-tDCS before and after the stimulation) to see if HD-tDCS of right inferior frontal gyrus improves social impairments in children with ASD. Participants will: * Receive a dose of 2 mA HD-tDCS of right inferior frontal gyrus lasting for 10 days. * Receive social functioning assessment, functional near-infrared spectroscopy and electroencephalography measurement before and after stimulation * Visit the clinic once every 2 weeks for checkups and tests, a total of 2 times.

Eligibility Criteria

Inclusion Criteria: * had to be 3-18 years old; be diagnosed with ASD (according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and Autism Diagnostic Interview - Revised (ADI-R). Exclusion Criteria: * with other comorbid neuropsychiatric conditions (i.e., schizophrenia spectrum disorders and mood disorders) or neurological disorders (i.e., head trauma and epilepsy).

Contact & Investigator

Central Contact

Xuerong Luo, Doctor

✉ luoxuerong@csu.edu.cn

📞 +86 731 85296820

Frequently Asked Questions

Who can join the NCT06723522 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 18 Years, studying Autism Spectrum Disorder (ASD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06723522 currently recruiting?

Yes, NCT06723522 is actively recruiting participants. Contact the research team at luoxuerong@csu.edu.cn for enrollment information.

Where is the NCT06723522 trial being conducted?

This trial is being conducted at Changsha, China.

Who is sponsoring the NCT06723522 clinical trial?

NCT06723522 is sponsored by Central South University. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology